ANGel platform possesses characteristics that give it the potential to bring innovation to the treatment of difficult-to-treat cancers
- Exceptional Targeting of Cancer Cells: It selectively delivers to cancer cells and minimizes side effects on normal cells.
- Customization of Treatment: The platform can accommodate various immune-oncology agents, enabling personalized treatment tailored to the patient's condition.
- High Treatment Efficacy: It effectively induces cancer cell apoptosis and improves survival rates.
- Sustained Effects: It maintains therapeutic effects for a long period following subcutaneous injection, helping prevent recurrence.
- Cost-Effective Development: It has lower development costs and shorter development timelines compared to existing immune-oncology drug development, enhancing the pace of cancer drug development and expanding access to treatment for more patients.